Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Medicine, Chemotherapy, Lung cancer, Exon, Oncology, and Epidermal growth factor receptor.
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.
Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions